FDA Orphan Drug Designation - Idiopathic Pulmonary Fibrosis
Filed with ASX · · 2 pages · English
Amplia Therapeutics Ltd. on 6ix
Story so far
Earlier from Amplia Therapeutics
- Quarterly Activities Report - March 2020 Qtr
- App 4C - Quarterly Cash Flow Report - March 2020 Qtr
- FDA Awards Orphan Drug Designation for Pancreatic Cancer
- Dr. John Lambert appointed as Managing Director
- Appendix 4C Cash Flow - Dec 2019 Qtr
Later from Amplia Therapeutics
- Preliminary Final Report - YE 31 March 2020
- Preliminary Toxicology Studies Support Phase1 Clinical Trial
- Entitlement Offer to Fund Phase 1 Clinical Trial
- Capital Raising - Investor Presentation
- Institutional Entitlement Offer Completed
Follow Amplia Therapeutics into a list and get an email when it puts out news.
Follow Amplia Therapeutics